Bleak Indicators For Acura Pharmaceuticals, Inc. (Nasdaq:ACUR), Closing At $0.16

Acura Pharmaceuticals, Inc. (Nasdaq:ACUR)

September 26th, 2018

Acura Pharmaceuticals, Inc. closed Tuesday up 19.23%, a $0.03 increase to close on $0.16. Two technical ‘scores’ for companies to be aware of are the Altman Z1 and the Piotroski2 scores. ACUR scored quite low for both, which could be indicators of trouble down the road (the Altman Z-Score is -197.80, and the Piotroski Score is 2).

ACUR outperformed the rest of the Healthcare sector which went down 0.28% today.

Market Sectors

The market sectors were mixed Wednesday with a majority of the sectors trending down. Consumer Discretionary saw the biggest increase of the day (0.59%), while Utilities saw the biggest drop (1.22%). Information Technology has seen the biggest year-to-date gain at 19%. The biggest loss this year has been the Consumer Staples sector declining 5.60%.

Consumer Discretionary saw the biggest turnaround from its 5-day performance of 0.43%, as it went up 0.59%. Materials and Financials saw turn arounds from their five day positive performance, Materials with a drop of 0.47%.

Sector Breakdown

  • Consumer Discretionary went up with a 0.59% change.
  • Energy went up with a 0.57% change.
  • Communication Services went up with a 0.09% change.
  • Information Technology went down with a -0.04% change.
  • Real Estate went down with a -0.10% change.
  • Healthcare went down with a -0.28% change.
  • Industrials went down with a -0.33% change.
  • Financials went down with a -0.38% change.
  • Materials went down with a -0.47% change.
  • Consumer Staples went down with a -0.73% change.
  • Utilities went down with a -1.22% change.

Acura Pharmaceuticals, Inc. Info

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Acura Pharmaceuticals, Inc.’s score is -197.80) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Acura Pharmaceuticals, Inc.’s score is ), and 9 is the best.

ACUR daily update
ACUR daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.